Haratani, Koji
Dana-Farber Cancer Institute
3 papers on CoChatORCID 0000-0002-1767-6854
Most cited papers
- Verified
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 1,003
- Verified
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell
Cancer Immunotherapy and Biomarkersinterferon and immune responses
Cited by 107
- Verified
KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 105
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free